DEPARTMENT OF DEFENSE - CONGRESSIONALLY DIRECTED MEDICAL RESEARCH PROGRAMS
  1. Home
  2. Research Programs
  3. Defense Medical Research and Development
  4. Research Highlights/News
  5. 2024 Defense Medical Research and Development Program

Defense Medical Research and Development

NEWS RELEASE

Released: July 10, 2024

Department of Defense
Congressionally Directed Medical Research Programs (CDMRP)
Defense Medical Research and Development Program (DMRDP)
Anticipated Funding Opportunities for Fiscal Year 2024 (FY24)

The FY24 Defense Appropriations Act provides funding for the Defense Medical Research and Development Program (DMRDP) to support DoD wide psychedelic medical clinical trials. The managing agent for the anticipated program announcements/funding opportunities is the Defense Health Agency with the CDMRP, at the U.S. Army Medical Research and Development Command (USAMRDC), providing execution management support on their behalf.

The DMRDP is providing the information in this pre-announcement to allow investigators time to plan and develop ideas for submission to the anticipated FY24 funding opportunities. This pre-announcement should not be construed as an obligation by the government. The FY24 DMRDP funding opportunity announcements for the following award mechanisms will be posted on the Grants.gov website. Pre-application and application deadlines will be available when the announcements are released.

Applications submitted to the FY24 DMRDP must propose clinical trials with eligible U.S. Service Members to evaluate treatments for posttraumatic stress disorder (PTSD) and/or traumatic brain injury (TBI) involving the use of covered psychedelic substances.

Covered psychedelic substances include:

  • 3,4-Methylenedioxy-methamphetamine (commonly known as MDMA )
  • psilocybin
  • ibogaine
  • 5-Methoxy-N,N-dimethyltryptamine (commonly known as 5-MeO-DMT )
  • plant-based alternative therapies
Award Mechanism Eligibility Key Mechanism Elements Funding
Clinical Trial Award Independent investigators at all career levels

Eligibility limited to:

  • A department or agency of the federal government or a state government
  • An academic institution
  • A research foundation partnering with a DoD intramural organization
  • An active-duty Service Member study population, which may include members of the reserve components, is required.
  • Treatment may involve the use of covered psychedelic substances alone or in conjunction with other evidence-based treatments.
  • Proposed projects may range from small proof-of-concept trials through large-scale trials to determine efficacy.
  • Inclusion of preliminary data relevant to the proposed clinical trial is required.
  • Department of Justice Drug Enforcement Agency application and licensure is required for work with controlled substances.
  • Submission of a Letter of Intent is required prior to full application submission.
  • Maximum funding of $4.9 million for total costs (direct plus indirect costs)
  • Maximum period of performance is 3 years.

A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline. All applications must conform to the final funding opportunity announcements that will be available for downloading from the Grants.gov website. The application package containing the required forms for each award mechanism will also be found on Grants.gov. A listing of all CDMRP and other USAMRDC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420.

Submission deadlines are not available until the funding opportunity announcements are released. For email notification when announcements are released, subscribe to program-specific news and updates under "Email Subscriptions" on the eBRAP homepage at https://eBRAP.org. For more information about the DMRDP or other CDMRP-administered programs, please visit the CDMRP website (https://cdmrp.health.mil/).

Point of Contact:

CDMRP Public Affairs
301-619-9783
usarmy.detrick.medcom-cdmrp.mbx.cdmrp-public-affairs@health.mil


Last updated Wednesday, July 10, 2024